Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Gross Margin (2016 - 2025)

Historic Gross Margin for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 51.83%.

  • Pharma's Gross Margin rose 37700.0% to 51.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 46.2%, marking a year-over-year decrease of 100100.0%. This contributed to the annual value of 48.7% for FY2025, which is 58000.0% down from last year.
  • As of Q3 2025, Pharma's Gross Margin stood at 51.83%, which was up 37700.0% from 46.95% recorded in Q2 2025.
  • Pharma's 5-year Gross Margin high stood at 67.86% for Q3 2021, and its period low was 30.72% during Q4 2022.
  • Moreover, its 5-year median value for Gross Margin was 48.06% (2024), whereas its average is 50.51%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 470600bps in 2021, then crashed by -247300bps in 2024.
  • Pharma's Gross Margin (Quarter) stood at 43.66% in 2021, then dropped by -30bps to 30.72% in 2022, then skyrocketed by 112bps to 65.2% in 2023, then crashed by -38bps to 40.47% in 2024, then rose by 28bps to 51.83% in 2025.
  • Its Gross Margin stands at 51.83% for Q3 2025, versus 46.95% for Q2 2025 and 46.67% for Q1 2025.